These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 20069338)

  • 1. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.
    Burris HA; Jones SF; Williams DD; Kathman SJ; Hodge JP; Pandite L; Ho PT; Boerner SA; Lorusso P
    Invest New Drugs; 2011 Jun; 29(3):467-72. PubMed ID: 20069338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
    Gomez HL; Philco M; Pimentel P; Kiyan M; Monsalvo ML; Conlan MG; Saikali KG; Chen MM; Seroogy JJ; Wolff AA; Escandon RD
    Anticancer Drugs; 2012 Mar; 23(3):335-41. PubMed ID: 22123335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.
    Blagden SP; Molife LR; Seebaran A; Payne M; Reid AH; Protheroe AS; Vasist LS; Williams DD; Bowen C; Kathman SJ; Hodge JP; Dar MM; de Bono JS; Middleton MR
    Br J Cancer; 2008 Mar; 98(5):894-9. PubMed ID: 18319713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study.
    Souid AK; Dubowy RL; Ingle AM; Conlan MG; Sun J; Blaney SM; Adamson PC
    Pediatr Blood Cancer; 2010 Dec; 55(7):1323-8. PubMed ID: 20712019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose.
    Holen KD; Belani CP; Wilding G; Ramalingam S; Volkman JL; Ramanathan RK; Vasist LS; Bowen CJ; Hodge JP; Dar MM; Ho PT
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):447-54. PubMed ID: 20461380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.
    Lee CW; Bélanger K; Rao SC; Petrella TM; Tozer RG; Wood L; Savage KJ; Eisenhauer EA; Synold TW; Wainman N; Seymour L
    Invest New Drugs; 2008 Jun; 26(3):249-55. PubMed ID: 17962907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors.
    LoRusso PM; Goncalves PH; Casetta L; Carter JA; Litwiler K; Roseberry D; Rush S; Schreiber J; Simmons HM; Ptaszynski M; Sausville EA
    Invest New Drugs; 2015 Apr; 33(2):440-9. PubMed ID: 25684345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors.
    Infante JR; Kurzrock R; Spratlin J; Burris HA; Eckhardt SG; Li J; Wu K; Skolnik JM; Hylander-Gans L; Osmukhina A; Huszar D; Herbst RS
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):165-72. PubMed ID: 21638123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
    Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma.
    Hollebecque A; Deutsch E; Massard C; Gomez-Roca C; Bahleda R; Ribrag V; Bourgier C; Lazar V; Lacroix L; Gazzah A; Varga A; de Baere T; Beier F; Kroesser S; Trang K; Zenke FT; Klevesath M; Soria JC
    Invest New Drugs; 2013 Dec; 31(6):1530-8. PubMed ID: 24077982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
    Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.
    Jones R; Vuky J; Elliott T; Mead G; Arranz JA; Chester J; Chowdhury S; Dudek AZ; Müller-Mattheis V; Grimm MO; Gschwend JE; Wülfing C; Albers P; Li J; Osmukhina A; Skolnik J; Hudes G
    Invest New Drugs; 2013 Aug; 31(4):1001-7. PubMed ID: 23329066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
    Chao J; Synold TW; Morgan RJ; Kunos C; Longmate J; Lenz HJ; Lim D; Shibata S; Chung V; Stoller RG; Belani CP; Gandara DR; McNamara M; Gitlitz BJ; Lau DH; Ramalingam SS; Davies A; Espinoza-Delgado I; Newman EM; Yen Y
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):835-43. PubMed ID: 22105720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
    Sewak S; Sorich J; O'Leary J
    Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.
    Fox E; Aplenc R; Bagatell R; Chuk MK; Dombi E; Goodspeed W; Goodwin A; Kromplewski M; Jayaprakash N; Marotti M; Brown KH; Wenrich B; Adamson PC; Widemann BC; Balis FM
    J Clin Oncol; 2010 Dec; 28(35):5174-81. PubMed ID: 21060028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.
    Holen K; DiPaola R; Liu G; Tan AR; Wilding G; Hsu K; Agrawal N; Chen C; Xue L; Rosenberg E; Stein M
    Invest New Drugs; 2012 Jun; 30(3):1088-95. PubMed ID: 21424701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer.
    Tsimberidou AM; Akerley W; Schabel MC; Hong DS; Uehara C; Chhabra A; Warren T; Mather GG; Evans BA; Woodland DP; Swabb EA; Kurzrock R
    Mol Cancer Ther; 2010 Dec; 9(12):3410-9. PubMed ID: 21159616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Tang PA; Siu LL; Chen EX; Hotte SJ; Chia S; Schwarz JK; Pond GR; Johnson C; Colevas AD; Synold TW; Vasist LS; Winquist E
    Invest New Drugs; 2008 Jun; 26(3):257-64. PubMed ID: 18038218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors.
    Gordon MS; Ilaria R; de Alwis DP; Mendelson DS; McKane S; Wagner MM; Look KY; LoRusso PM
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):21-7. PubMed ID: 23228983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.
    Shimizu T; LoRusso PM; Papadopoulos KP; Patnaik A; Beeram M; Smith LS; Rasco DW; Mays TA; Chambers G; Ma A; Wang J; Laliberte R; Voi M; Tolcher AW
    Clin Cancer Res; 2014 Oct; 20(19):5032-40. PubMed ID: 25107918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.